We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Large Prostate Cancer Prevention Trial Opens

By HospiMedica staff writers
Posted on 30 Jul 2001
A new study of 32,400 men at more than 400 sites over 12 years will seek to determine if two dietary supplements, selenium and vitamin E, can protect against prostate cancer, the most common form of cancer, after skin cancer, in men. More...
Called SELECT, the trial was launched by the U.S. National Cancer Institute (NCI) and a network of researchers known as the Southwest Oncology Group (SWOG).

Selenium and vitamin E, both naturally occurring nutrients, are antioxidants. They are capable of neutralizing toxins known as free radicals that might otherwise damage the genetic material of cells and possibly lead to cancer. The nutrients were chosen for this study because of the favorable results of two other large cancer prevention trials. In a study of selenium to prevent nonmelanoma skin cancer, investigators found that while the supplement did not reduce skin cancer, it decreased the incidence of prostate cancer in men by more than 60%. Another trial, in which beta carotene and vitamin E were tested to prevent lung cancer, showed that men who took vitamin E had 32% less prostate cancer.

"SELECT is the critical next step for pursuing the promising leads we saw for prevention of prostate cancer,” said Leslie Ford, M.D., associate director for clinical research in NCI's Division of Cancer Prevention. "The only way to determine the real value of these supplements for prostate cancer is to do a large clinical trial focused specifically on this disease.”




Related Links:
Southwest Oncology Group
National Cancer Institute

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.